Supernus Pharmaceuticals, Inc. Forecast, price target & analysts
Supernus Pharmaceuticals, Inc. Target price 2026 - Analyst rating & recommendation
Supernus Pharmaceuticals, Inc. Classifications & Recommendation
Supernus Pharmaceuticals, Inc. Price Target
| Target Price | $66.30 |
| Price | $43.04 |
| Potential |
54.04%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Supernus Pharmaceuticals, Inc. 2027 .
The average Supernus Pharmaceuticals, Inc. target price is $66.30.
This is
54.04%
register free of charge
$70.35
63.45%
register free of charge
$55.55
29.07%
register free of charge
|
|
| A rating was issued by 11 analysts: 9 Analysts recommend Supernus Pharmaceuticals, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Supernus Pharmaceuticals, Inc. stock has an average upside potential 2027 of
54.04%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 718.95 | 903.51 |
| 8.63% | 25.67% | |
| EBITDA Margin | 14.19% | -3.83% |
| 44.29% | 127.00% | |
| Net Margin | -5.36% | 16.84% |
| 148.04% | 414.06% |
7 Analysts have issued a sales forecast Supernus Pharmaceuticals, Inc. 2026 . The average Supernus Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Supernus Pharmaceuticals, Inc. EBITDA forecast 2026. The average Supernus Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 Supernus Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2026. The average Supernus Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.68 | 2.62 |
| 151.52% | 485.29% | |
| P/E | 16.45 | |
| EV/Sales | 2.36 |
7 Analysts have issued a Supernus Pharmaceuticals, Inc. forecast for earnings per share. The average Supernus Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Supernus Pharmaceuticals, Inc....
Current Supernus Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Jul 09 2026 |
| Stifel |
Locked
➜
Locked
|
Locked | Dec 19 2025 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Oct 29 2025 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Oct 23 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Oct 09 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Sep 30 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Aug 29 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Jul 09 2026 |
|
Locked
Stifel:
Locked
➜
Locked
|
Dec 19 2025 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Oct 29 2025 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Oct 23 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Oct 09 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Sep 30 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Aug 29 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
